Skip to main content

Table 3 Estimated subdistribution hazard ratios for temporal lobe injury (TLI) using univariate and multivariate competing risk regression models

From: Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study

Variable Univariate analyses Multivariate analyses
sHRa (95% CI) P value sHRa (95% CI) P value
N-classification
 N2–3 vs N0–1 1.330 (0.853–2.070) 0.210   
AJCC 2010 stage
 IVB vs IVA 0.806 (0.265–2.450) 0.700   
Chemotherapy
 Induction (vs no) 2.270 (0.794–6.480) 0.130   
 Concurrent (vs no) 0.744 (0.445–1.240) 0.260   
 Adjuvant (vs no) 1.080 (0.618–1.890) 0.790   
 Concurrent cetuximab or nimotuzumab (vs no) 1.760 (0.803–3.850) 0.160   
 Nasopharynx boost (vs no) 2.430 (0.919–6.440) 0.074   
Overall treatment time (OTT)
 > 45 vs ≤45 0.941 (0.567–1.560) 0.810   
 Temporal lobe Dmax (per Gy increase) 1.260 (1.150–1.370) < 0.001   
 Temporal lobe D1cc (per Gy increase) 1.270 (1.180–1.370) < 0.001 1.500 (1.212–1.856) < 0.001
 Temporal lobe V20 (per cc increase) 1.040 (1.030–1.060) < 0.001 1.072 (1.009–1.139) 0.024
 Temporal lobe V30 (per cc increase) 1.060 (1.040–1.090) < 0.001   
 Temporal lobe V40 (per cc increase) 1.100 (1.070–1.120) < 0.001   
 Temporal lobe V50 (per cc increase) 1.130 (1.090–1.170) < 0.001   
 Temporal lobe V60 (per cc increase) 1.190 (1.130–1.250) < 0.001   
 Temporal lobe V70 (per cc increase) 1.380 (1.260–1.510) < 0.001   
  1. sHRa subdistribution hazard radio